Oligonucleotide-based Therapeutics Summit

Delivering Oligonucleotides with Specificity, Mitigating Off-Target Effects, and Improving Cellular Uptake to Target Undruggable Molecules.

The Oligonucleotide-based Therapeutics Summit is uniting leaders in RNA chemistry, delivery science, and translational biology to advance oligonucleotides as a pioneering therapeutic class.

With multiple approvals, growing clinical validation across diverse indications, and breakthroughs in chemical modifications and delivery platforms, oligonucleotides are no longer a niche field, they’re rapidly becoming the modality of choice for tackling both validated and previously “undruggable” targets. The question is no longer if oligonucleotides will reshape the therapeutic landscape, but how fast.

This December in Boston, unite with leading experts from Secarna, Genentech, Avidity Bioscience, Dyne Therapeutics, Biogen, Novo Nordisk, Stoke Therapeutics, and more as they reveal cutting-edge insights spanning discovery to late-stage development. Discover how advances in RNA chemistry and delivery are unlocking safer, more precise therapies, broadening therapeutic potential, and driving faster patient impact. Don’t miss the only meeting dedicated exclusively to unlocking the full therapeutic potential of oligonucleotides.


URLs:
Website: https://go.evvnt.com/3247806-0?pid=2874
Brochure: https://go.evvnt.com/3247806-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic and Not-for-Profit Organizations - Conference + Pre-Conference Workshop Day: USD 3597.00,
Academic and Not-for-Profit Organizations - Conference Only: USD 2599.00,
Service and Solution Providers - Conference + Pre-Conference Workshop Day: USD 5097.00,
Service and Solution Providers - Conference Only: USD 3699.00

Speakers: Cody Desjardins, Senior Director, Dyne Therapeutics, David Guay, Vice President, Innovation and Technology, Feldan Therapeutics, David Parfitt, Senior Scientist, ProQR Therapeutics, Frank Jaschinski, Chief Scientific Officer, Secarna, Ganesh Iyer, Chief Executive Officer and Founder, Opprtna Therapeutics, HAGEN Cramer, Chief Technology Officer, QurAlis, Jace Jones, Associate Professor, University of Maryland, Jack Ostrowski Director, Protein Sciences, Avidity Biosciences, Jean-Christophe Hoflack, Senior Principal Scientist, F Hoffmann-La Roche, Kevin Guckian, Senior Director, Biogen, Marcin Kortylewski Professor, City of Hope, Meena Indrakanti Senior Vice President, Translational Drug Metabolism, Pharmacokinetics and Clinical Pharmacology, Stoke Therapeutics, Michael Cummings, Professor, University of Maryland, Paloma Giangrande, Senior Vice President of Discovery and Translational Biology, Orbital Therapeutic, Pawan Kumar Director, Oligonucleotide Chemistry, Biomarin, Puneet Anand, PhD, Regeneron, Santhosh Kumar, Thatikonda Senior Principal Scientist, Genentech, Tama Evron Director, Platform Discovery, Dyne Therapeutics, Utsav Saxena, Head of Systems Biology, Novo Nordisk